Collapsing glomerulopathy: A 30-year perspective and single, large center experience by Cossey, Nicholas et al.




Collapsing glomerulopathy: A 30-year perspective
and single, large center experience
Nicholas Cossey
Washington University School of Medicine in St. Louis
Christopher P. Larsen
Washington University School of Medicine in St. Louis
Helen Liapis
Washington University School of Medicine in St. Louis
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Cossey, Nicholas; Larsen, Christopher P.; and Liapis, Helen, ,"Collapsing glomerulopathy: A 30-year perspective and single, large
center experience." Clinical Kidney Journal.10,4. 443-449. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6124
CKJ REVIEW
Collapsing glomerulopathy: a 30-year perspective and
single, large center experience
L. Nicholas Cossey1, Christopher P. Larsen1 and Helen Liapis1,2
1Renal Pathology Division, Arkana Laboratories, Little Rock, AR, USA and 2Department of Pathology &
Immunology, Washington University School of Medicine, St Louis, MO, USA
Correspondence and offprint requests to: Helen Liapis; E-mail: helen.liapis@arkanalabs.com
Abstract
Collapsing glomerulopathy (CGP) is a pattern of kidney injury seen on renal biopsy with multiple associations and etiolo-
gies. It is most commonly described in African-Americans and others with recent African ancestry. The disease is rapidly
progressive and often presents with abrupt onset of renal failure and nephrotic-range proteinuria. Since its description
30 years ago, this entity has transformed from amorphologic diagnosis typically seen in the setting of HIV infection to a
complicated diagnosis with numerous etiologies, many of which are associated with underlying apolipoprotein L1 (APOL1)-
risk variants or other genetic disorders. We review the evolution of CGP, and its history and proposed pathomechanisms.
We also present the disease spectrum from our experience with emphasis on recognizing the lesion, distinguishing from
mimics and linking the histopathological pattern to a specific cause. Our understanding continues to evolve as clinicians
and scientists work toward a more complete understanding of the molecular pathways of injury in this disease and how
these might be disrupted for therapeutic purposes. Much still remains to be discovered in CGP as the molecular underpin-
nings leading to disease are still not completely understood and no effective treatment exists despite the high morbidity.
Based on this rapid evolution, CGP is a modern template of how we diagnose and think about kidney disease. The story of
CGP represents the current shift in nephrology and nephropathology frommorphology-alone-based diagnosis to a compre-
hensive approach including molecular diagnostics. We believe this new, holistic approach will lead to pathogenesis-
centered diagnoses that will help to individualize risk stratification and treatment protocols.
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Birth and evolution of a newmorphologic
entity: collapsing glomerulopathy
In the mid-1980s, the first descriptions of a very aggressive pro-
teinuric disease with a glomerular pattern of collapse were pub-
lished. Weiss et al. wrote the first clinicopathologic findings of
what we now view as collapsing glomerulopathy (CGP) [1]. They
described six African-American patients who developed rapidly
progressive renal failure, nephrotic syndrome, glomerular tuft
collapse, podocyte hyperplasia and significant tubulointerstitial
damage (Figure 1A–C). Differently from the previously reported
human immunodeficiency virus (HIV)/acquired immune defi-
ciency syndrome (AIDS) phenotype [2, 3], these patients had
negative serology for the HIV. Using a computerized medical re-
cord system, they convincingly argued that these patients rep-
resented a new disease entity [2, 3]. The association between
HIV and CGP largely came about following a report by Cohen
and Nast. describing nine HIV-positive patients with proteinuria
and rapidly progressive renal disease [4]. Morphologically, these
patients consistently showed unique segmental tuft collapse
with overlying podocyte hypertrophy and hyperplasia. In add-
ition, microcystic tubular dilatation with inspissated,
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Fig. 1. CGP, morphologic indicators of APOL1-related nephropathy, underlying etiologies and mimics. (A–D) HIV–CGP. Biopsy from a 31-year-old African-American (AA)
woman, HIV-positive, who presented with nausea and vomiting, hematuria and proteinuria, acute and chronic renal failure, creatinine 3.4mg/dL. Serum albumin
2.1 g/L. (A) Global capillary loop wrinkling (collapse) and massive podocyte proliferation. Podocytes are filled with lipid droplets (silver stain 200). (B) Markedly dilated
tubules filled with eosinophilic material (H þ E 100). (C) Tubular reticular inclusions in endothelial cell [electron microscopy (EM)20 000]. (D) Multinucleated podo-
cytes (thick arrow) lining collapsed capillary loops (thin arrow). Also present are cytoplasmic osmiophilic inclusions (lysosomes). (E, F) APOL1 nephropathy. Renal bi-
opsy is from a 51-year-old AA man who presented with hypertension, nephrotic-range proteinuria and chronic kidney disease. He was subsequently found to have
two APOL1 risk alleles. (E) Biopsy shows segmental glomerular loop collapse and podocyte proliferation over the collapsed loops (silver 200). Numerous solidified glo-
meruli were present (not shown). (F) Tubular atrophy thyroidization type and severe arteriosclerosis (PAS 100). (G–I) Lupus membranous with CGP. Patient is a 27-
year-old woman with nephrotic syndrome recently diagnosed with lupus. (G) CGP is shown. There are no spikes (silver stain 200). (H) Immunofluorescence showed
diffuse granular capillary loop deposits [(immunoglobulin G IgG) 200]. (I) EM shows subepithelial and early intramembranous deposits. (J–M) Lupus with APOL1. The
patient was an AA woman with well documented lupus serology seen for follow-up because of persistent proteinuria in spite of aggressive therapy. APOL1 genotyping
revealed two risk alleles (Figure 2). (J) Segmental pilling up of visceral podocytes mimicking epithelial crescent (silver 200). (K) Immunofluorescence showed diffuse
full house immune deposits [immunofluorescence (IF)50]. (L) Crescent-like proliferation and marked tubular dilatation (silver 100). (M) EM shows subendothelial
and mesangial deposits. (N, O) Interferon-induced CGP. A 54-year-old man with multiple sclerosis treated with interferon beta1 alpha. Presented with proteinuria more
than 5g/24h and preserved renal function. (N) Segmental capillary loop collapse and podocyte proliferation (silver 200). (O) No tubulointerstitial damage (trichrome
100). (P–R) Ischemic CGP in allograft kidney. The patient is a 43-year-old AA with deceased donor kidney 5 years prior to this biopsy. He presented with severe hyper-
tension (HTN) and creatinine 4.5mg/dL and increasing proteinuria. (P) Retracted glomerulus shows podocyte proliferation (silver 200). (Q) Arteriolar thrombosis is
identified adjacent to the glomerulus in (P) (silver stain 200). (R) Diffuse C4d positivity in peritubular capillaries consistent with antibody mediated rejection (IF100).
(S) Epithelial crescents mimic CGP. Shown is a glomerulus with podocyte proliferation (arrow points to mitotic podocyte) with no necrosis or fibrin deposits and vague
capillary loop collapse. Patient was a 62-year-old man with rapidly progressing glomerulonephritis and pending serologies at the time of biopsy. No known predispos-
ing factors for CGP. (T) Diabetes with CGP. The patient was a known diabetic for 10 years with acute onset nephrotic-range proteinuria. Biopsy shows podocyte prolifer-
ation over glomerular diabetic nodules (silver stain 200).
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proteinaceous material and extensive protein resorption drop-
lets within proximal tubular epithelium were described. While
this entity shared many similarities with the entity Weiss et al.
reported, it was termed HIV-associated nephropathy (HIVAN)
due to the strong correlation with HIV/AIDS infection. In 1994,
Detwiler et al. reported 16 predominantly African-American pa-
tients, with rapidly progressive renal failure, proteinuria and
segmental to global glomerular tuft collapse [5]. These findings
shared extensive morphologic overlap with the patients
described by Weiss et al., and Cohen et al. and the findings were
corroborated by a comprehensive study of 30 cases reported by
D’Agati et al. in 1989 [6]. In the mid-1990s, the original observa-
tions were confirmed by several authors. In 1994, Detwiler et al.
reported 16 predominantly African-American, HIV-negative, pa-
tients with features similar to those described by Weiss et al. [1],
including rapidly progressive renal failure, proteinuria and seg-
mental to global glomerular tuft collapse [5]. Subsequently,
others corroborated these results and with a larger study by
Valeri et al., the term collapsing focal segmental glomeruloscle-
rosis was introduced in the literature [7, 8].
Later, studies by Barisoni et al. suggested a common patho-
logic mechanism between CGP and HIVAN that leads to a dysre-
gulated podocyte phenotype in both HIVAN and CGP [9]. This
concept of common mechanisms of injury was based on three
lines of evidence. First, both entities showed complete loss of
normal podocyte phenotype utilizing known markers of podo-
cytes (CALLA, GLEPP1, Podocalyxin, Synaptopodin, WT1, P27
and p57 were decreased while Cyclin D1, Cyclin E, Cyclin A, Ki-
67, Desmin, Cytokeratin and CD68 were increased). Second,
comparable numbers of podocytes were noted to enter the cell
cycle in both diseases, in contrast to normal podocytes that are
physiologically arrested, post-mitotic cells. Lastly, both diseases
showed identical ultrastructural cytoarchitecture. Barisoni et al.
subsequently proposed the term podocytopathy for diseases
of the podocyte and developed a classification structure [nor-
mal glomerular histology—minimal change disease (MCD);
segmental glomerulosclerosis (FSGS); mesangial sclerosis—dif-
fuse mesangial sclerosis (DMS); and capillary loop collapse—
CGP] [10].
More recently, a concept has been proposed that is termed
podocyte mitotic catastrophe (MC) that attempts to explain the
etiology of podocytopathies such as collapsing lesions [11]. To
explain this concept, we can look to collapsing lesions in
HIVAN. There is evidence that HIV can infect podocytes (and
parietal epithelial cells), leading to podocyte mitosis and a
switch to a proliferative podocyte phenotype where proliferat-
ing podocytes attempt to divide unsuccessfully. The morpho-
logic result of this switch in phenotype is podocyte multi-
nucleation (Figure 1D), previously thought of as a compensatory
mechanism of podocyte repair. However, this phenotype switch
and podocyte multi-nucleation has now been suggested to be a
distinct podocyte death mechanism—MC [11, 12]. MC is believed
to be a conflict in the podocyte cell cycle that prevents podo-
cytes from dividing and leads to their detachment from the glo-
merular basement membrane (GBM). This is a separate
mechanism from crescent formation where ruptured capillary
loops allow blood leakage into Bowman’s space, which pro-
motes epithelial cell proliferation (both visceral and parietal)
[13]. The connection of podocyte proliferation and aberrant cell
death through attempted mitosis (MC) is still a new concept
that may potentially help explain the pathogenesis of CGP.
However, to date, little has been studied experimentally or clin-
ically on this topic despite its intriguing implications.
Throughout the discovery phase of CGP, several secondary
etiologies/associations were reported such as renal vascular is-
chemia, infection other than HIV (hepatitis C, HTLV-1, parvo-
virus B19 and loa loa filariasis), systemic lupus erythematosus,
drugs [such as pamidronate, interferon (Figure 1N and O), ana-
bolic steroids and heroin], hematologic neoplasia and familial
types [14–22]. Throughout the 2000s, CGP saw mostly growth in
its associations without significant change in its morphologic
descriptions.
CGP in the era of genetics
The discovery of the apolipoprotein L1 (APOL1) G1 and G2 risk
variants (located on the long arm of chromosome 22 at position
13.1) would prove to be tremendously important in shaping our
understanding of CGP [23]. These commonly occurring variants
in the APOL1 gene are responsible for the increased burden of
non-diabetic renal disease affecting African-Americans [24].
Patients with any combination of two of these risk alleles in-
herit a markedly increased risk of renal disease and progression
to end-stage renal disease.
The G1 variant is a pair of two non-synonymous single nu-
cleotide polymorphisms (SNPs) in almost complete linkage dis-
equilibrium. The G2 variant is an in-frame deletion of the two
amino acid residues, N388 and Y389 [25]. The gene product,
APOL1 protein, is a minor component of high-density lipopro-
tein that is found in vascular endothelium, liver, heart, lung,
placenta, podocytes, proximal tubules and arterial cells [26].
The protein also has a secreted form that circulates in the blood
and is known for its roles in trypanosomal lysis, autophagic cell
death, lipid metabolism and other biological activities [27]. The
APOL1 risk variants are common in the African-American popu-
lation due to selection pressure related to the protection they
confer from Trypanosoma brucei rhodesiense infection [27].
The role of APOL1 in kidney health is still not entirely under-
stood but there is at least one report of an APOL1 null Indian
man who had no evidence of kidney disease while infected with
trypanosomes [28]. This suggests that APOL1 may be dispens-
able for normal kidney function and that APOL1 risk variants
may acquire toxic functions that damage the kidney. CGP has
been shown to be associated with the presence of homozygosity
for APOL1 risk alleles in a number of disease settings including
HIV, lupus nephritis, membranous glomerulopathy and in asso-
ciation with interferon and pamidronate treatment [17, 19, 29–
31]. It appears that both glomerular injury and inflammatory
‘second hits’ may potentiate kidney damage in patients
with APOL1 risk variants [25, 32]. In addition, while identifica-
tion of APOL1 risk variants requires genetic testing, Larsen et al.
have recently described key morphologic features [microcystic
tubular dilatation, thyroid-type tubular atrophy (Figure 1E and
F) and a predominance of solidified/disappearing-type global
glomerulosclerosis] that, when found in combination, have sig-
nificant association with underlying APOL1 gene risk variant
homozygosity [33].
CGP in children
While uncommon, CGP has been reported in children, especially
in the setting of underlying APOL1 risk variants [34]. Kopp et al.
described a pediatric subset of their cohort with two underlying
APOL1 risk variants [34]. While the pediatric patients showed
less FSGS than their older cohorts, CGP was identified within
this population, usually after 12 years of age [34]. Subsequent
studies of APOL1 in children have shown a more aggressive
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course of renal disease in those with homozygosity for APOL1
risk alleles [35].
In addition to the APOL1 association, other genetic diseases
may be associated with CGP in children, especially ones with
underlying mitochondrial dysfunction (action myoclonus—
renal failure syndrome, ZMPSTE24 mandibuloacral dysplasia/
action myoclonus, mitochondrial cytopathy coenzyme Q10
(CoQ10), CoQ2 deficiency and sickle cell anemia) [36]. Whether
mitochondria in general may represent a common pathogenic
pathway for CGP is intriguing because mitochondrial damage
induces cell death and cytochrome C release, which have also
been shown to play a role in CGP development [36, 37].
Another point to be considered in childhood CGP is the po-
tential morphologic resemblance of CGP and DMS. While these
entities are often straightforward to distinguish, both CGP and
DMS may show podocyte proliferation and differentiation may
be difficult in rare cases of DMS where mesangial sclerosis is
not present. However, this is a very rare occurrence as DMS fre-
quently shows additional glomerular findings (e.g. fetal glomer-
uli) and clinical manifestations (e.g. Denys–Drash syndrome)
that may help in differentiation [38]. As DMS may be caused by
treatable entities (CoQ2, CoQ10 and other mitochondrial en-
zyme deficiency), differentiation is imperative [36, 37].
CGP in the allograft kidney
CGP in the renal allograft has a similar set of potential etiologies
to CGP in the native kidney [39]. However, two potential scen-
arios deserve special attention. First, APOL1 risk variants are
still an important etiology of CGP in the renal allograft; however,
it is the APOL1 status of the allograft donor that is associated
with disease [40]. And, should CGP that is associated with donor
APOL1 risk variants be identified, correlation with the other
transplanted kidney (if both of the donor’s kidneys were trans-
planted) should be attempted as both will be affected [40]. The
occurrence of APOL1-associated kidney disease in renal trans-
plants has raised the important question of APOL1 gene testing
of allografts from high-risk populations. However, this topic is
controversial and would currently be difficult to implement due
to utility and turnaround-time limitations associated with gen-
etic testing [41].
Next, is the issue of how to interpret focal collapsing lesions
in the renal allograft in the setting of ischemia and microangi-
opathy (Figure 1P–R). Although primarily reported in native kid-
neys, collapsing lesions can be seen in thrombotic
microangiopathy (TMA) and other ischemic conditions in the
allograft, and often occur in glomeruli with significant microan-
giopathic injury (Figure 1Q) [42–44]. In this setting, there should
be a high threshold for the diagnosis of CGP. Features we find
helpful to suggest a diagnosis of CGP include involvement of
glomeruli that are seemingly uninvolved by microangiopathy
and background tubulointerstitial changes typically seen in CGP
(Figure 1G and H). Clinical symptoms supportive of CGP (neph-
rotic-range proteinuria and acute renal failure) are not uncom-
mon in TMA and may not be helpful. Descriptive diagnoses or
comments explaining the morphology in this setting are poten-
tially useful and alerts the nephrologist to monitor the patient
during and after treatment of the TMA to see if they have add-
itional clinical features to corroborate the presence of a concur-
rent CGP (such as an abnormal clinical course, APOL1 risk alleles
or a known secondary disease such as HIV).
CGP: causes and distribution from a large
database
In our renal biopsy, database over a 15.5-year period, 1201 cases
of CGP were identified representing 1.4% of renal biopsies per-
formed over that time period (70 000). Over our study interval
(the last 6months of 2015) a total of 88 sequential CGP cases
were retrieved as a focused subset. These cases represent 1.3%
of the total renal biopsies over this period, a frequency similar
to that of the entire database. Our biopsy database was queried
for cases containing the term ‘CGP’ within the diagnosis or com-
ment (July–December 2015). Inclusion criteria for this study con-
sisted of: native and adequate renal biopsy tissue for diagnosis,
unequivocal diagnosis of CGP and absence of proliferative lupus
nephritis with crescents. A total of 88 cases met inclusion crite-
ria and were included in the cohort.
Average patient age was 44 (11–83 range) years old with a
nearly equal male:female ratio (48% male, 52% female). As in
previous studies, a marked predilection for African ancestry
was noted, with 84% of patients being African-American (see
Table 1). The reasons for renal biopsy varied, with the most
common presentation being nephrotic-range proteinuria and
acute renal failure (51% of patients). Chronic kidney disease was
noted in a fraction (17%) of patients. Markedly elevated serum
Table 1. Clinical findings and etiologies






Average serum creatinine (mg/dL) 4.15 (0.8–17.8 range)
Average proteinuria (g/day) 11.2 (0.8–31 range)
Nephrotic syndrome (%) 86
Hypertension (%) 92
Etiology of collapsing glomerulopathy (%)
Idiopathic disease (APOL1 not tested) 77
HIV/AIDS (HIVAN) 17




Table 2. CGP associations from published studies and our data
Infectious micro-organisms
HIV, parvovirus 19, cytomegalovirus, hepatitis C
Tuberculosis, Campylobacter enteritis
Autoimmune diseases
Lupus, lupus-like disease, connective tissue disease, Still’s disease
Hereditary
APOL1-related nephropathy
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creatinine values were common, with an average of 4.15mg/dL
(0.8–17.8mg/dL range), and proteinuria was most often of the
nephrotic range (72% of patients) with an average of 11.2 g/day
(0.8–31 g/day range). Hematuria was noted in 28% of patients
(however, this data point may not be reliable as <50% of pa-
tients had this data available for review). Hypertension was fre-
quently present (92% of patients) at the time of biopsy.
While a potential etiology of CGP was identified in a small
subset of patients, 77% of patients (68 patients) had idiopathic
disease (see Table 2); however, none of these patients was
tested for APOL1 risk variants. The most common etiology iden-
tified in these patients was HIV/AIDS (17%; 15 patients) and
among these 15 patients with HIV/AIDS, 10 were African-
American, one was Caucasian and four had unknown ancestry.
Three non-African ancestry patients (3%) showed ischemic
glomerular and tubulointerstitial changes in addition to arterio-
sclerosis, and a history of hypertension and an ischemic eti-
ology was favored. A single patient (1%) had a history of recent
heroin use and likely represented heroin nephropathy while an-
other single patient (1%) had a history of active hepatitis C in-
fection in the absence of other known etiologies of CGP.
Additionally, eight patients had a history of systemic lupus
erythematosus, with four showing membranous lupus nephritis
(ISN/RPS Class V) (Figure 1G–I). APOL1 genetic testing was only
requested and performed in two patients, both with systemic
lupus, and both (2%) showed homozygosity for APOL1 risk al-
leles (Figure 1J–M and Figure 2). This overall distribution of etiol-
ogies is comparable to other, similar case series in CGP [5, 7, 8,
45, 46].
A second biopsy diagnosis was present in 52% (46/88) of pa-
tients. The most common secondary diagnosis by a wide mar-
gin was acute tubular injury followed by glomerular immune
complex deposition, acute/chronic tubulointerstitial nephritis,
diabetic glomerulopathy and non-proliferative lupus nephritis.
The difficult diagnosis; entities mimicking CGP
In most CGP cases, morphologic diagnosis is straightforward
when histopathologic criteria are applied. However, cases do
arise that are more nuanced and raise considerable
disagreement even among experienced renal pathologists as to
whether a diagnosis of CGP should be invoked. These cases
often show some features of CGP (Figure 1S) but lack convincing
glomerular morphologic changes or the characteristic accom-
panying tubulointerstitial changes are not present. Also, glom-
erular epithelial hyperplasia can become particularly florid,
appearing as crescentic glomerulonephritis. This particular dif-
ficulty is often encountered on a background of membranous
glomerulopathy, diabetic glomerulopathy, or membranous
lupus nephritis or TMA, further complicating interpretation [30,
31, 47]. As no data exist detailing any specific test to differenti-
ate crescents from CGP this formidable question is often rele-
gated to experience and opinion. In the case of underlying
diabetic glomerulopathy, Salvatore et al. have recently ad-
dressed the question of collapsing lesions superimposed on dia-
betic glomerulopathy (Figure 1T) and their study suggested that
these lesions might be attributable to ischemia [47]. Similarly,
CGP in TMA is thought to be due to ischemia. The recent study
by Buob et al. addressed the association from the endothelial in-
jury point of view, bringing this mechanism into the pathogen-
esis of CGP [42].
Overall, we find the presence of fibrinoid necrosis, karyor-
rhexis, glomerular basement membrane rupture and red blood
cell casts to be helpful indicators of crescent formation while
the absence of these findings with the presence of protein re-
sorption droplets admixed with the hypertrophied and hyper-
plastic podocytes, significant tubular intracytoplasmic protein
resorption drops, microcystic tubular dilatation, thyroid type
tubular atrophy and a predominance of solidified or
disappearing-type global glomerulosclerosis suggests CGP.
Conclusions
CGP is a morphologic lesion representing a common endpoint
from multiple etiologies. It is a podocytopathy that is often sec-
ondary to APOL1 risk variants but has also been associated with
infection, drugs, ischemia, hematologic neoplasia and autoim-
mune disease. Morphological features of CGP are time-tested
and well-recognized today. However, there are several con-
founding morphologies that may provide diagnostic difficulty.
Fig. 2. APOL1 genotyping. Taqman SNP genotyping data performed on a real-time PCR system with primers designed to detect the APOL1 risk alleles G1 (rs73885319)
and G2 (rs71785313). The genotypes cluster according to whether they are homozygous for the risk allele being tested (dark blue), homozygous wild type (red) or hetero-
zygous for the risk allele (green). The black boxes represent no-template controls. This patient (light blue) is heterozygous for each risk allele, indicating that she is
compound heterozygous for G1 (A) and G2 (B) APOL1 risk alleles and, therefore, at risk for APOL1-associated nephropathy.
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The discovery of APOL1 risk variants changed the way we
understand and classify CGP and provide, in part, a unifying eti-
ology for some of the underlying associations, leading to a more
pathogenesis-based approach to this multifaceted diagnosis.
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